TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion
TOP-Study (Tacrolimus Organ Perfusion): A Prospective Multicenter Trial for Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion
Sponsor: Ludwig-Maximilians - University of Munich
This PHASE2/PHASE3 trial investigates Graft Dysfunction and Graft Failure and is currently terminated or withdrawn. Ludwig-Maximilians - University of Munich leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2_PHASE3
-
Apr 2017 — Jun 2018 [monthly]
Terminated PHASE2_PHASE3
Status: Unknown Status → Terminated · Phase: NA → PHASE2_PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Apr 2017 [monthly]
Unknown Status NA
First recorded
Oct 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ludwig-Maximilians - University of Munich
For direct contact, visit the study record on ClinicalTrials.gov .